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ABSTRACT
Purpose: To investigate if cetuximab induces epithelial to mesenchymal transition 
(EMT) and activation of cancer associated fibroblast (CAF) in the tumors of patients 
with squamous cell carcinoma of the head and neck (SCCHN).
Methods: Cetuximab was administered for two weeks prior to surgery to 20 
treatment-naïve patients. Five untreated patients were included as controls. Tumor 
biopsies were performed at baseline and before surgery. Gene expression profiles and 
quantitative real-time PCR (qRT-PCR) analysis of the pre-and post-treatment biopsies 
were compared. To further investigate EMT and CAF, correlations between previously 
described EMT and CAF markers and our microarray data set were calculated.
Results : Gene expression profile analyses and qRT-PCR showed that some of the 
genes modified by cetuximab were related to CAFs and EMT (ZNF521, CXCL12, ASPN, 
OLFML3, OLFM1, TWIST1, LEF1, ZEB1, FAP). We identified 2 patient clusters with 
different EMT and CAF characteristics. Whereas one cluster showed clear upregulation 
of expression of genes implicated in CAF and EMT including markers of embryologic 
pathways like NOTCH and Wnt, the other did not.
Conclusion: Even if EMT and CAFs are implicated in cetuximab resistance in pre-
clinical models, we demonstrate for the first time that these molecular processes may 
occur clinically early on.
INTRODUCTION
With an incidence of over 650.000 people per year, 
squamous cell carcinoma of the head and neck (SCCHN) 
is the sixth most common cancer worldwide. Despite 
combined treatment in patients with stage III/IV SCCHN, 
long-term survival rates remain low in advanced stages, 
and chemoradiation regimens have reached their upper 
limit of tolerability [1]. Therefore, the investigation of new 
targets, based on the biology of the disease, is of major 
importance.
Cetuximab is recommended as treatment for 
patients with locally advanced SCCHN. This chimeric 
IgG1 monoclonal antibody (mAb) specifically binds 
to the epidermal growth factor receptor (EGFR) with 
high affinity. EGFR is a transmembrane tyrosine kinase 
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receptor belonging to the HER/erbB family. Up to 
90% of SCCHN express high levels of EGFR [2]. The 
overexpression of EGFR and tumor growth factor-alpha 
(TGF-α) is associated with poor prognosis [3, 4] and 
radioresistance [3, 5].
Cetuximab improves the overall survival when 
associated with radiation therapy in locally advanced 
SCCHN, or with platinum-based chemotherapy in 
incurable disease [6, 7]. However, with single agent 
objective response rates between 6% and 13%, only a 
minority of patients benefit from anti-EGFR mAbs [7, 
8]. In contrast to colon cancer, where RAS mutations 
predict treatment resistance [9], little is known about the 
potential mechanisms of cetuximab resistance in SCCHN. 
Hypotheses to explain anti-EGFR resistance include the 
acquisition of oncogene activating mutations, activation of 
alternative signaling growth pathways, or modifications in 
tumor composition [10-12].
Components of the tumor microenvironment have 
been implicated in treatment resistance and have been 
shown to influence tumor growth and progression [13-15]. 
Epithelial to mesenchymal transition (EMT), a process 
in which cancer cells lose cell-to-cell adhesion and gain 
invasive properties, has been described in preclinical 
models, including SCCHN, as a possible mechanism 
of EGFR therapy resistance [11]. Cancer-associated 
fibroblasts (CAFs), essential components of the tumor 
microenvironment, may also modulate EGFR treatment 
sensitivity and promote tumor growth [12]. Evidence of 
this in real clinical situations is, however, lacking. 
We have previously shown that pre-operative 
administration of cetuximab in a window opportunity 
study was safe and active [16]. We extended the study 
to compare pre- and post-cetuximab tumor biopsies for 
gene and protein expression. We show here that cetuximab 
has a strong anti-tumoral effect, but that it also induces 
significant modifications in the tumor that may promote 
subsequent tumor growth and aggressiveness.
RESULTS
Clinical results
Cetuximab was administered for two weeks prior to 
surgery to 20 treatment-naïve SCCHN patients selected 
for surgical treatment, as previously reported [16]. 
Ninety percent of the patients achieved a 18FDG-PET 
response, but the majority had no significant macroscopic 
tumor shrinkage. In patients treated with cetuximab, 
histopathological analysis of the tumor specimens at 
surgery showed reduced tumor cellularity, downregulation 
of tumor proliferation and decreased phospho-EGFR 
compared to untreated controls [16]. 
Cetuximab monotherapy induced modifications in 
tumor composition
Initially, the impact of cetuximab on gene expression 
was obtained through a global analysis of the Affymetrix 
gene expression data with the aim of determining which 
genes are differently expressed between the pre- and post-
treatment biopsies, and in which biological processes 
they are involved. The expression data from the baseline 
biopsies (BC) and the operative biopsies (OC) was 
compared. Only high quality samples were used for the 
analysis (n = 19 before and n = 15 after cetuximab). 
Upregulated genes, with at least two times higher mean 
expression (delta >1) per group compared to the others, 
were selected. Out of these, 284 Affymetrix spots were 
significantly differentially expressed (P < 0.05) between 
the BC and OC (Supplementary Table 1). The expression 
of 96 genes (114 spots) upregulated in the BC compared 
to the OC, and of 138 genes (170 spots) significantly 
more highly expressed in the OC, was normalized and 
visualized in Genesis (Figure 1A).
ClueGO [17] functional analysis revealed that 
these genes were involved in pathways associated with 
angiogenesis, epithelial cell proliferation, cell adhesion, 
extracellular matrix organization, inflammatory response 
and negative regulation of response to DNA damage 
stimulus (Figure 1B). Interestingly, the 96 genes 
downregulated by cetuximab were mainly associated with 
epithelial cell proliferation, tissue morphogenesis, positive 
regulation of angiogenesis, and nucleoside salvage. In 
contrast, the 138 genes upregulated after cetuximab were 
specifically involved in extracellular matrix organization, 
cell adhesion and immune-related domains such as 
inflammatory response, humoral immune response, 
complement and coagulation cascade, and leukocyte 
migration (Figure 1C, Supplementary Figure 1A). 
Among the genes differently expressed, 41 had a 
strong fold change in their expression (an absolute fold 
change of 1.8 i.e. 0.85 Log2 scale, and a corrected P for 
multiple testing with a Benjamini-Hochberg test (BH) 
below 5%). 
Six of these genes were associated with 
inflammation: ADAMDEC1, APOC1, C3, CD163, ACKR1, 
VSIG4. Another 20 genes are known to be implicated in 
cancer-related processes. 
Some of these cancer-related genes were associated 
with processes occurring in the extracellular matrix 
and related to DCN: CXCR4/CXCL12 axis, SELP, vWF, 
COL3A1, SCARA, SPARCL1. Other genes were related 
to CAFs and EMT (ZNF521, CXCL12, ASPN, OLFML3, 
OLFM1) (Supplementary Table 2). 
Following cetuximab treatment, the overexpression 
of selected genes related to either cancer stroma processes 
or CAFs, and EMT, was confirmed by quantitative real-
time PCR (qRT-PCR) and immunochemistry (IHC). A 
significantly higher expression of DCN (P = 0.0010), 
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Figure 1: Biological role of the differently expressed genes between the pre- and post-treatment tumor biopsies. A. Gene 
expression in biopsies taken at baseline (BC, n = 19) and under operative (OC, n = 15) conditions was investigated. Upregulated genes 
having at least two times higher mean expression (delta >1) per group compared to the others were selected. The expression of significantly 
differentially expressed genes (P < 0.05) was normalized and visualized in Genesis. BC and OC are coloured in black and grey, respectively. 
Genes with high (Hi) and low (Lo) expression are shown in red and green, respectively. B. ClueGO functional analysis of the 104 genes 
(284 Affymetrix spots) significantly differentially expressed between OC and BC. Gene Ontology, KEGG and Reactome pathways were 
used. Functionally grouped network with pathways and terms as nodes linked based on their kappa score. The node size represents the term 
significance. Fusion was applied to remove redundant terms. Only pathways with P < 0.05 after Benjamini correction for multiple testing 
were included in the network. Functionally related groups partially overlap. Not grouped terms are shown in grey. C. Distribution of the 
differently expressed genes in BC (n = 96) and OC (n = 138) on the network of pathways from B.. Terms with high expression genes in BC 
and OC are shown in red and green, respectively. The color gradient shows the gene proportion of each cluster associated with the term. 
Equal proportions of the two clusters are represented in grey. Pathways and associated genes are presented in Supplementary Figure. 1.
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SPARCL1 (P = 0.0207), OLFM1 (P = 0.0010), OLFML3 
(P = 0.0016), and CXCL12 (P = 0.0011) was observed 
after cetuximab but not in the biopsies of the untreated 
patients (data not shown). A good correlation was 
obtained between the Affymetrix and qPCR measured 
gene expression if the genes had a higher expression 
than a Log2 intensity of 3 in the Affymetrix data (e.g. r 
= 0.84 for OLFM1), confirming the reproducibility of the 
microarray-based results. IHC staining on the resected 
tumor specimens confirmed the upregulation of decorin in 
the cetuximab treated group when compared to the control 
group (P = 0.0068) (Supplementary Figure 1B and 1C). In 
addition, we found inverse correlations between decorin 
expression, measured by qRT-PCR or IHC, and the 
residual tumor cellularity of the surgical specimens (r = 
-0.64, P = 0.0006; and r = -0.55, P = 0.0067, respectively), 
as well as with 18FDG/PET response, the primary 
endpoint of our clinical trial (r = -0.50, P = 0.0120; and 
r = -0.4380, P = 0.0207, respectively) (Supplementary 
Figure 1D, 1E and 1F). P21WAF1/CIP1, a potent 
inhibitor of cyclin-dependant kinases, has been shown to 
be upregulated after the interaction between decorin and 
EGFR. P21 overexpression was also demonstrated after 
cetuximab by IHC (Supplementary Figure 1G) but was not 
found in the untreated samples (data not shown).
 Cetuximab induced EMT
In the second phase of this study, a detailed analysis 
aimed at investigating the impact of cetuximab treatment 
on the EMT process was performed. Seven genes, 
known to be related to EMT in SCCHN (ZEB1, TWIST1, 
TWIST2, LEF1, VIM, SNAI1 and SNAI2) [18, 19], were 
analyzed. Their expression was normalized and visualized 
in Genesis (Figure 2A). Interestingly, the known EMT 
markers LEF1, TWIST1, and ZEB1, showed significantly 
increased expression in post-treatment biopsies (Figure 
2B). Increased expression in OC was observed for 
TWIST2 and VIM. SNAI1 was minimally expressed in 
the microarray (expression <3), and therefore filtered 
out for further analysis. These results were confirmed by 
qPCR in the BC and OC samples of cetuximab treated 
and untreated patients. A significantly higher expression 
was observed for TWIST1 (P < 0.05) (Figure 2C). To 
investigate which other genes behave in a similar way 
after cetuximab treatment, correlations between the six 
selected EMT genes and all the other Affymetrix tested 
genes were calculated with CluePedia [20]. The top 10 
genes, with the highest correlation (r > 0.6) with each 
of the six markers, were found to be enriching the EMT 
known marker network (Figure 2D). Interestingly, DCN 
was also found among the EMT enriched genes, which 
positively correlated with TWIST1 (r = 0.83), TWIST2 
(r = 0.83), ZEB1 (r = 0.76) and VIM (r = 0.65). ClueGO 
functional analysis revealed that these genes are involved 
in pathways relating to EMT, stem cell proliferation, and 
the development and positive regulation of cell motility 
(Figure 2E). 
The expression of the EMT enriched genes was 
heterogeneous in patients with a complete set of time 
points (data not shown). The unsupervised clustering 
of the fold increase or decrease in OC compared to BC 
revealed two patient groups with different EMT pathway 
related modifications. Overall, cluster 1 patients had a 
significantly increased expression of EMT-related genes 
(P < 0.0001), compared to cluster 2 patients. The fold 
change visualization thus allowed the identification of 
patient groups with similar changes in EMT-related 
gene expression after cetuximab treatment (Figure 2F, 
Supplementary Table 3). Statistically significant (P < 0.05) 
gene modifications between both time points are shown in 
Supplementary Figure 2a for all patient samples, and in 
Figure 2G for patients cluster 1. Genes with a P - value in 
between 0.05 and 0.1 are represented in Supplementary 
Figure 2B and Supplementary Figure 2C, according to 
cluster 1 and 2. 
Interestingly, the same patient clusters were 
obtained when analyzing the fold change of genes 
known to be involved in the EMT pathway from Gene 
Ontology (GO). Among these genes, Wnt pathway 
(LEF1, TWIST1, SFRP2, WNT5A, DAB2), TGFβ pathway 
(TGFB1I1, TGFB3, DAB2) and NOTCH1 pathway 
(HEYL) related genes, as well as LOXL3 and NFATC1, 
showed significantly increased expression after cetuximab 
treatment in patients from cluster 1 (Figure 2H). DAB2, 
LEF1 and TWIST1 were found in both the EMT enriched 
and the EMT GO genes. Other genes implicated in 
the NOTCH1 pathway (HAS2, HEY1, HEY2), the 
WNT pathway (WNT2 and WNT4), and the TGFβ 
pathway (TGFBR3), as well as HGF, showed increased 
expression (P < 0.1) after treatment in cluster 1 patients 
(Supplementary Figure 2D). In contrast, only few genes 
had expression modification in cluster 2 (Supplementary 
Figure 2E).
To validate these results and further investigate 
EMT, additional analyses were performed by IHC. 
E-cadherin and vimentin were immunohistochemically 
stained on BC and OC biopsies of the cetuximab and 
control groups. We observed a significant decrease in 
E-cadherin expression and a significant increase in 
vimentin in tumor cells in the cetuximab group but not 
in the controls (data not shown), as semi-quantified 
by histoscore (Figure 3A). Patient clusters were also 
confirmed in this analysis; a decrease in E-cadherin and 
an increase in vimentin were found only in tumors from 
cluster 1 (Figure 3B, 3C).
Cetuximab induced activation of CAFs
To assess the impact of cetuximab on CAF-related 
genes, a methodology similar to that for EMT was 
applied. Six known CAF markers: ACTA2, CXCL12, 
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Figure 2: Expression pattern of epithelial to mesenchymal transition (EMT) markers and related genes after treatment 
with cetuximab in SCCHN patients. A. The expression of known EMT related genes in biopsies taken at baseline (BC, n = 19) and 
under operative (OC, n = 15) conditions. BC and OC are coloured in black and grey, respectively. Data was normalized. Genes with high 
and low expression are shown in red and green, respectively. B. Affymetrix measured EMT marker expression in OC (yellow) and BC 
(blue). Bar charts represent the mean (± SEM), and the median expression is shown in blue. Wilcoxon-Mann-Whitney test was applied 
(* 0.01≤ P < 0.05). C. Relative RNA expression levels (RT-qPCR) of EMT markers in OC (yellow) and BC (blue). Whiskers represent 
means ± SD. D. CluePedia network showing EMT markers (red) together with the top 10 correlating genes with each of these markers 
(blue). SNAI1 had low expression ( < 3). The edges represent Pearson r values (P > 0.6). Negative correlations are shown with a sinusoidal 
line. Correlation examples are shown for DCN and EMT makers. E. ClueGO functional analysis of the EMT markers and enriched genes 
described at D.. Functionally grouped network with terms as nodes linked based on their kappa score. The node size represents the term 
enrichment significance. Fusion was applied to remove redundant terms. Only pathways with P < 0.05 after Benjamini correction for 
multiple testing were included in the network. Functionally related groups partially overlap. F. The fold change expression (OC-BC) of 
EMT markers and enriched genes described at D. in SCCHN patients with complete time points (n = 15). The fold change matrix was 
normalized and hierarchical clustered (Kendall’s tau, Average Linkage). Two patient clusters were revealed. Increased and decreased 
expression in OC compared to BC is shown in red and green, respectively. Significantly increased expression after cetuximab treatment 
of G. EMT markers and enriched genes described at D., as well as of H. genes associated to the epithelial and mesenchymal transition 
pathway from Gene Ontology (GO), in patients from cluster 1 F.. Bar charts represent the mean (± SEM) in OC (yellow) and BC (blue), and 
the median expression is shown in blue. Wilcoxon-Mann-Whitney test was applied (* 0.01≤ P < 0.05, ** 0.001≤ P < 0.01, ***P < 0.001). 
Genes with a similar trend can be seen in Supplementary Figure 2.
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FAP, PDGFRB, S100A4 and TGFB1 [18] were analyzed, 
and their expression was compared between BC and OC 
(Figure 4A, 4B). A significantly increased expression in 
OC was observed for FAP, with a similar trend for ACTA2, 
CXCL12 and PDGFRB. 
The expression of CXCL12 was further investigated 
by qRT-PCR. A significantly upregulated CXCL12 
expression was observed in the cetuximab group but not 
in the controls, validating the microarray data (P = 0.004 
respectively) (Figure 4C). 
CAF enriched genes were further selected from 
the genes with the strongest correlation with the CAF 
markers, and were visualized together in a network 
(Figure 4D). Correlations between PDGFRB and other 
CAF-related genes were shown. Interestingly, ZEB1 was 
part of both networks and correlated very well with many 
EMT and CAF related markers. Genes showing similar 
behaviour to the CAF markers after cetuximab treatment 
were involved in pathways relating to wound healing, the 
collagen metabolic process [21] and extracellular matrix 
organization (Figure 4E), as revealed by the ClueGO 
functional analysis.
Interestingly, the fold change of the CAF enriched 
gene expression observed in paired OC and BC samples 
identified the same patient clusters as obtained with the 
EMT enriched genes (Figure 4F, Supplementary Table 4). 
Statistically significant genes (P < 0.05) were represented 
in Figure 4G for cluster 1 and in Supplementary Figure 
3A for all patients. Genes with a similar trend are shown 
in Supplementary Figure 3B and 3C, according to clusters 
1 and 2.
Since GO does not yet provide a CAF-related 
term gene association, a previously published CAF gene 
signature defined in colon cancer was analysed [22]. 
Significantly differentially expressed genes are represented 
in Figure 4H, and gene expression modifications with a 
P < 0.1 are represented in Supplementary Figure 3D and 
Supplementary Figure 3E. 
CAF enriched genes were further analysed together 
with a previously published stromal signature defined in 
breast cancer [23]. Many of the CAF and stroma-related 
genes were involved in the same biological functions 
(Supplementary Figure 3F). 
Strong correlations between EMT and CAF enriched 
genes (r > 0.8) and markers (r > 0.6) were observed inside 
the tumor (Supplementary Figure 4A and 4B). Several 
genes, such as ZEB1, ZEB2, FYN and LAMA4, were found 
to be enriched in both EMT and CAF, suggesting similar 
functional implications.
To further validate both patient clusters, we tested 4 
previously described SCCHN molecular subtypes in our 
microarray dataset [24]. Whereas most of the genes in the 
OC biopsy of cluster 1 were related to the mesenchymal 
phenotype, cluster 2 expressed genes related to the 
atypical phenotype after the treatment (Supplementary 
Figure 4C and 4D).
DISCUSSION
This «window study» provided a unique opportunity 
to monitor the molecular modifications induced by 
cetuximab in treatment-naïve patients with SCCHN. 
Besides its antitumoral effect, we demonstrate here that 
cetuximab induces major tumor modifications. These 
Figure 3: The impact of cetuximab treatment in SCCHN patients on E-cadherin and vimentin. Representative 
immunohistochemical (IHC) staining of E-cadherin and vimentin on baseline (BC) and post-cetuximab (OC) tumor biopsies in a typical 
patient included in the group treated with cetuximab A.. Histoscore for E-cadherin B. and vimentin B. comparing BC and OC biopsies, as 
well as biopsies from patients from clusters 1 and 2 defined in Figure 2F. Histoscore = (% weakly stained cells) + (% moderately stained 
cells) x 2 + (% strongly stained cells) x 3.
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Figure 4: Expression pattern of cancer-associated fibroblast (CAF) markers and related genes after treatment with 
cetuximab in SCCHN patients. A. The expression of known CAF related genes in baseline (BC, n = 19, black) and post-operative 
(OC, n = 15, grey) biopsies. Data was normalized. High and low expression is shown in red and green, respectively. B. CAF marker 
expression in OC (yellow) and BC (blue). Bar charts represent the mean (± SEM), and the median expression is shown in blue. Wilcoxon-
Mann-Whitney test was applied (* 0.01 ≤ P < 0.05, 0.05 ≤ P < 0.1). C. RT-qPCR measured expression of CXCL12 in OC (yellow) and 
BC (blue). Whiskers represent means ± SD. D. CluePedia network showing CAF markers (red) together with correlating genes (blue). 
The edges represent Pearson r values (P > 0.6). Negative correlations are shown with a sinusoidal line. Correlation examples are shown 
for PDGFRB and enriched genes. E. ClueGO functional analysis of the CAF markers and enriched genes described at D.. Functionally 
grouped network with terms as nodes linked based on their kappa score. The node size represents the term enrichment significance. Fusion 
was applied to remove redundant terms. Only pathways with P < 0.05 after Benjamini correction for multiple testing were included in 
the network. Functionally related groups partially overlap. F. The fold change expression (OC-BC) of CAF markers and enriched genes 
described at D. in patients with complete time points (n = 15). The fold change matrix was normalized and hierarchical clustered (Kendall’s 
tau, Average Linkage). Two patient clusters were revealed. Increased and decreased expressionis shown in red and green, respectively. 
Significantly increased expression after cetuximab treatment of G. CAF markers and enriched genes described at D., as well as of H. genes 
known to be associated with cancer-associated fibroblasts25 in patients from cluster 1 F.. Bar charts represent the mean (± SEM) in OC 
(yellow) and BC (blue) and the median expression is shown in blue. Wilcoxon-Mann-Whitney test was applied (* 0.01 ≤ P < 0.05, ** 0.001 
≤ P < 0.01, ***P < 0.001). Genes with a similar trend can be seen in Supplementary Figure. 3.
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modifications included genes and proteins implicated in 
the extracellular matrix, linked with CAFs or related to 
EMT. 
We observed significant upregulation of decorin 
expression, which may play a role in tumor control, as 
suggested by the inverse correlations observed between 
decorin expression and the residual tumor cellularity of the 
surgical specimens. This small leucine-rich proteoglycan 
may inhibit tumor cell growth, migration, angiogenesis 
and metastasis [25, 26] by interaction with different 
receptor tyrosine kinases such as EGF [27, 28], other 
erbB family members [29], c-Met [30] and IGF-1R [31] 
and upregulation of p21WAF1/CIP1 (p21) via a p-53 
independent pathway [32]. SPARCL1 (hevin), another 
matricellular protein was also found to be upregulated 
in our cetuximab treated tumors. This protein seems 
to modulate the structure of the extracellular matrix by 
regulating decorin levels and collagen fibril assembly [33]. 
Besides an increased expression of matrikines, 
which may play a role in the control of tumor growth 
and decreased tumor invasion, we observed tumor 
modifications that may lead to tumor regrowth, or have 
the potential to be implicated in cetuximab resistance. We 
showed extracellular matrix modifications of the tumor and 
upregulation of factors generally secreted by CAFs such as 
CXCL12, ASPN [34] and OLFML3 [35, 36]. CAFs may 
induce resistance to cetuximab [12]. Cetuximab-induced 
growth inhibition was reduced in SCCHN cell lines co-
cultured with CAFs through CAF-derived soluble factors, 
and CAF induced resistance to cetuximab was partly 
abolished by matrix metalloproteinase inhibitors. 
The upregulation of CXCL12 is of particular 
interest. CXCL12, also known as stromal cell-derived 
factor-1α, is the ligand of CXCR4. Activation of the 
CXCR4/CXCL12 axis can lead to tumor proliferation 
and can promote neoangiogenesis, cancer cell invasion 
and metastasis, and EMT [37, 38]. Moreover, CXCR4 
may have a role in cancer stem cells in SCCHN [39]. It 
is also expressed on circulating tumor cells of metastatic 
carcinoma and in melanoma patients [40]. Inhibitors of the 
CXCR4/CXCL12 axis are currently under development 
[41]. 
Furthermore, we showed high correlations between 
the known CAF markers and other genes potentially 
implicated in EMT, including a high correlation between 
PDGFRB and LAMB1, and PDGFR and ZEB1. It has 
been described that PDGF is required for the translation 
of LAMB1 during EMT [42]. 
Finally, increased EMT has been shown to be 
a potential mechanism of anti-EGFR resistance in 
pre-clinical models [11, 43, 44]. We investigated the 
expression of different EMT markers and showed that 
some patients have upregulation of EMT markers after 
cetuximab. We identified two groups with different EMT 
characteristics. Whereas cluster 1 patients showed clear 
upregulation of expression of multiple genes implicated 
in EMT and embryologic pathways like NOTCH and Wnt, 
cluster 2 patients did not show the same modifications in 
gene expression. These findings may have therapeutic 
implications since the addition of Wnt inhibitors to 
EGFR inhibitors showed increased activity [45, 46] in 
non-small cell lung carcinoma cells (NSCLC). Our study 
showed increased expression of markers implicated in 
the noncanonical frizzled2 pathway (SFRP2, WNT5A, 
FYN), which has been recently identified by Gujral et al 
[47]. Inhibition of this pathway, implicated in EMT and 
cell migration, shows encouraging results on xenografts. 
It is currently unknown whether cetuximab enriches 
mesenchymal-like cells or promotes the transformation 
of epithelial to mesenchymal cell types by EMT. The 
correlation between DCN and EMT markers plays in favor 
of the first hypothesis. 
One limitation of our work is that only three doses 
of cetuximab were given to avoid delaying standard 
surgical curative treatment for ethical reasons. Our model 
can therefore only investigate early occurring molecular 
mechanisms. Other designs are needed to fully explore 
the long-term acquired resistance mechanisms of anti-
EGFR monoclonal antibodies. Other limitations are the 
low number of patients, a possible bias due to tumor 
heterogeneity as well as the difficulties to perform more 
precise protein validation of the gene expression profiles 
due to the limited amount of tumor tissues we can collect 
safely in a real clinical situation.
Our previous work and this study collectively 
demonstrate that cetuximab reduces tumor cellularity 
and induces modifications in the peritumoral 
microenvironment of SCCHN. Even if EMT and CAFs 
have shown to be possibly implicated in cetuximab 
resistance in pre-clinical models, our data show that these 
molecular processes may also occur very early on in the 
clinic. Our work paves the way for further investigation of 
novel therapies targeting these pathways in SCCHN.
MATERIALS AND METHODS
Patients
Cetuximab was administered for two weeks prior to 
surgery to 33 treatment-naïve patients (NCT00714649). 
Five control patients were included. They were not treated 
with cetuximab but were subject to the same biopsy and 
imaging requirements. Details of the eligibility criteria, 
pretreatment evaluation, safety, and clinical results have 
been published [16]. The clinical and translational parts 
of the study were approved by the Independent Ethics 
Committee and the Belgian Health Authorities and 
conducted in accordance with the Declaration of Helsinki 
(October 2000). It was prospectively planned to perform 
translational research and patients gave their informed 
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consent for repeated biopsies. For homogeneity, only the 
patients included in the expansion part of the trial (n = 
20) and the control patients (n = 5) were included in the 
translational research reported here. 
Tissue samples
Tumor biopsies were taken from the middle of 
the tumor surface at two different time points: (i) before 
treatment, baseline condition samples (BC), and (ii) on the 
day of surgery, operation condition samples (OC). At each 
time point, one biopsy was stored in RNAlater® for up to 
one week at 4°C and then frozen at -80°C, and another 
was fixed in 4% formalin and embedded in paraffin.
Immunohistochemistry and pathologic evaluation
Slides coming from tumor biopsies and the resected 
tumor were haematoxylin and eosin (H&E) stained to 
confirm the presence of viable tumor cells. 
Immunohistochemical (IHC) staining was 
performed on 4-µm paraffin embedded tumor sections 
for p21WAF (cell signaling, 1/75), E-cadherin (cell 
signaling, 1/100) and vimentin (cell signaling, 1/100), 
and on surgical specimens for decorin (R&D, 1/40). All 
the stained slides were digitized by a slide scanner (Mirax 
Scan; Zeiss, Jena, Germany). The percentage of the 
stained area was evaluated using Frida software (http://
bui3.win.ad.jhu.edu/frida). p21 and decorin expression 
were subsequently quantified using an optical microscope 
at 400x and 200x magnification, respectively. E-cadherin 
and vimentin staining on tumor cells was blindly assessed 
for each patient by histoscore as previously published [16]. 
RNA extraction and microarrays
Total RNA was extracted using the miRNeasy Mini 
Kit from Qiagen (Venlo, Netherlands). 
After checking the concentration (NanoDrop), 
yield and integrity (Agilent 2100 Bioanalyzer), RNA 
samples of high quality (RNA integrity number (RIN) > 
6, mean 8.1) were selected for gene expression profiling 
by microarray. According to these criteria, one BC and 
five OC biopsies were not analyzed by microarray. 250 ng 
of RNA was amplified and labeled using the Affymetrix 
GeneChip® 3’ IVT Express Kit. RNA was hybridized 
overnight to Affymetrix GeneChip HG-U133 Plus 2.0 
(High Wycombe, UK), then stained and washed on an 
Affymetrix Gene Chip® Fluidics Station 450. The array 
was then scanned to produce an image data file (DAT) and 
a cell intensities data file (CEL). A report file (RPT) was 
generated and a chip data file (CHP) was generated from 
the CEL file. The CEL file was then exported, ready for 
importing the analysis. 
Based on the bioinformatic analysis quality control 
procedure, no microarrays were removed. The dataset 
was normalized using the GCRMA method. Normalized 
expression levels are given in Log2 scale.
Reverse transcriptase polymerase chain reaction 
(RT-PCR) and real time quantitative RT-PCR 
(qRT-PCR)
Synthesis of first-strand cDNA for use in qRT-PCR 
was carried out on 500 ng of total mRNA and subjected 
to reverse transcription using SuperScript® III First-Strand 
Synthesis SuperMix for qRT-PCR, as described by the 
manufacturer (Invitrogen). 
The following predesigned TaqMan® gene 
expression assays and TaqMan® Gene Expression Master 
Mix were obtained from AB Applied Biosystems:
DCN (Hs00370384_m1), CXCL12 (Hs00171022_
m1), ZEB1 (Hs00232783_m1), OLFML3 (Hs00220180_
m1), p21 (Hs00355782_m1), TWIST1 (Hs00361186_m1), 
TWIST2 (Hs00382379_m1), LEF1 (Hs01547250_m1).
Human glyceraldehyde 3 phosphate dehydrogenase 
(GAPDH) (AB Applied Biosystems NM_002046.3) was 
used as an internal control as previously described (20). 
qRT-PCR was performed in a 10μl total reaction mixture 
using a CFX96™ (Bio-Rad) thermal cycler. The thermal 
cycling conditions were 50°C for two minutes followed by 
95°C for 10 minutes, 95°C for 15 seconds and 60°C for 60 
seconds. The last two steps were repeated for 40 cycles. 
Real-time PCR was performed in duplicate for each gene. 
The qRT-PCR data was presented as delta Ct values 
of the investigated genes relative to GADPH.
The fold change (2-ΔΔCt) in gene expression in 
each paired sample was calculated using the formulas: 
gene expression ΔCt = average gene expression Ct 
minus average GADPH Ct; gene expression ΔΔCt = 
gene expression ΔCt OC minus gene expression ΔCt BC. 
Results were expressed in Log2 scale.
Statistical methods
The normality of the data was tested using the 
Shapiro-Wilk test. The Student’s t-test and the Mann-
Whitney-Wilcoxon rank-sum test were used for pairwise 
comparisons of parametric and non-parametric data, 
respectively. Pearson and Wilcoxon correlations were 
performed. A P - value < 0.05 was considered statistically 
significant. Benjamini-Hochberg method was used for 
multiple testing correction. 
Genes were mapped on Gene Ontology (GO), 
Kyoto Encyclopedia of Genes and Genomes (KEGG) 
and Reactome (data was downloaded on 01.02.2014) and 
enriched (P < 0.05 after Bonferroni step-down correction), 
non redundant pathways and terms were visualized in 
ClueGO networks [17]. 
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Using CluePedia [20], correlations between the 
expression of epithelial to mesenchymal transition (EMT) 
and cancer-associated fibroblast (CAF) markers and other 
Affymetrix tested genes, were calculated. Genes with 
the highest correlation were extracted and enriched the 
EMT and CAF networks, respectively. The expression 
difference in the OC compared to the BC was calculated 
for the EMT and CAF markers and for the enriched genes. 
The expression difference matrix was normalized and 
clustered in Genesis (Kendall’s tau distance measurement, 
Average Linkage).
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